Literature DB >> 11589619

Application of cell engineering technology to the tumour immunotherapeutic drug: a review.

Z N Chen1, J L Xing, H J Bian, L Mi, J L Jiang.   

Abstract

The concept of cell engineering is frequently mentioned in recent years. It's a comprehensive technology which is very powerful and useful. By using it, scientists can produce many kinds of proteins and other biological moleculars in large scale that are in great demand for the human being. Among these products, most can be used for tumor immunotherapy and have been confirmed to be very effective in tumour control or subsidiary treatment. Of them, most common and useful drugs include three sorts; tumour vaccines, cell factors and monoclonal antibodies. The paper will discuss in detail related drugs application advances in tumour immunotherapy. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11589619     DOI: 10.1006/cbir.2001.0753

Source DB:  PubMed          Journal:  Cell Biol Int        ISSN: 1065-6995            Impact factor:   3.612


  3 in total

1.  Involvement of CD147 in overexpression of MMP-2 and MMP-9 and enhancement of invasive potential of PMA-differentiated THP-1.

Authors:  Jun Zhou; Ping Zhu; Jian Li Jiang; Qing Zhang; Zhen Biao Wu; Xi Ying Yao; Hao Tang; Ning Lu; Yong Yang; Zhi Nan Chen
Journal:  BMC Cell Biol       Date:  2005-05-17       Impact factor: 4.241

2.  Function of HAb18G/CD147 in invasion of host cells by severe acute respiratory syndrome coronavirus.

Authors:  Zhinan Chen; Li Mi; Jing Xu; Jiyun Yu; Xianhui Wang; Jianli Jiang; Jinliang Xing; Peng Shang; Airong Qian; Yu Li; Peter X Shaw; Jianwei Wang; Shumin Duan; Jin Ding; Chunmei Fan; Yang Zhang; Yong Yang; Xiaoling Yu; Qiang Feng; Biehu Li; Xiying Yao; Zheng Zhang; Ling Li; Xiaoping Xue; Ping Zhu
Journal:  J Infect Dis       Date:  2005-01-25       Impact factor: 5.226

3.  The interaction of HAb18G/CD147 with integrin alpha6beta1 and its implications for the invasion potential of human hepatoma cells.

Authors:  Jing-yao Dai; Ke-feng Dou; Cong-hua Wang; Pu Zhao; Wayne Bond Lau; Ling Tao; Ya-mei Wu; Juan Tang; Jian-li Jiang; Zhi-nan Chen
Journal:  BMC Cancer       Date:  2009-09-23       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.